Latest From Ascletis Inc.
Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
Acquisition of gene therapy company Calimmune expands on CSL Behring's hematology franchise and fits rare disease business model, plus adds platform tech with wide application for CSL's portfolio.
- Antisense, Oligonucleotides
- Large Molecule
- Specialty Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Infectious & Viral Diseases
- Parent & Subsidiaries
- Ascletis Inc.
- Senior Management
Jinzi J Wu, PhD, Pres. & CEO
Joseph Musto, Sr. Dir., Dev.
- Contact Info
Phone: 571- 8538-9729
1785 Jianghai Rd., Bldg. 1, Ste. 804
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.